BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li ZJ, Ou-Yang PH, Han XP. Profibrotic effect of miR-33a with Akt activation in hepatic stellate cells. Cell Signal. 2014;26:141-148. [PMID: 24100264 DOI: 10.1016/j.cellsig.2013.09.018] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Lee J, Kim Y, Friso S, Choi SW. Epigenetics in non-alcoholic fatty liver disease. Mol Aspects Med. 2016; Nov 23. [Epub ahead of print]. [PMID: 27889327 DOI: 10.1016/j.mam.2016.11.008] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 9.7] [Reference Citation Analysis]
2 López-Sánchez GN, Dóminguez-Pérez M, Uribe M, Chávez-Tapia NC, Nuño-Lámbarri N. Non-alcoholic fatty liver disease and microRNAs expression, how it affects the development and progression of the disease. Ann Hepatol 2021;21:100212. [PMID: 32533953 DOI: 10.1016/j.aohep.2020.04.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Ran LJ, Liang J, Deng X. Latest advances in understanding of relationship between microRNAs and hepatic fibrosis. Shijie Huaren Xiaohua Zazhi 2016; 24(36): 4813-4819 [DOI: 10.11569/wcjd.v24.i36.4813] [Reference Citation Analysis]
4 Lu CH, Hou QR, Deng LF, Fei C, Xu WP, Zhang Q, Wu KM, Ning BF, Xie WF, Zhang X. MicroRNA-370 Attenuates Hepatic Fibrogenesis by Targeting Smoothened. Dig Dis Sci. 2015;60:2038-2048. [PMID: 25686745 DOI: 10.1007/s10620-015-3585-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
5 Tan Y, Pan T, Ye Y, Ge G, Chen L, Wen D, Zou S. Serum microRNAs as potential biomarkers of primary biliary cirrhosis. PLoS One. 2014;9:e111424. [PMID: 25347847 DOI: 10.1371/journal.pone.0111424] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 5.5] [Reference Citation Analysis]
6 Schoepp M, Ströse AJ, Haier J. Dysregulation of miRNA Expression in Cancer Associated Fibroblasts (CAFs) and Its Consequences on the Tumor Microenvironment. Cancers (Basel) 2017;9:E54. [PMID: 28538690 DOI: 10.3390/cancers9060054] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 7.2] [Reference Citation Analysis]
7 Kumar V, Mahato RI. Delivery and targeting of miRNAs for treating liver fibrosis. Pharm Res 2015;32:341-61. [PMID: 25186440 DOI: 10.1007/s11095-014-1497-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
8 Portius D, Sobolewski C, Foti M. MicroRNAs-Dependent Regulation of PPARs in Metabolic Diseases and Cancers. PPAR Res 2017;2017:7058424. [PMID: 28167956 DOI: 10.1155/2017/7058424] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 6.6] [Reference Citation Analysis]
9 Mahmood S, Bhatti A, Syed NA, John P. The microRNA regulatory network: a far-reaching approach to the regulate the Wnt signaling pathway in number of diseases. J Recept Signal Transduct Res 2016;36:310-8. [PMID: 26523375 DOI: 10.3109/10799893.2015.1080273] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
10 Roy S, Benz F, Luedde T, Roderburg C. The role of miRNAs in the regulation of inflammatory processes during hepatofibrogenesis. Hepatobiliary Surg Nutr 2015;4:24-33. [PMID: 25713802 DOI: 10.3978/j.issn.2304-3881.2015.01.05] [Cited by in F6Publishing: 33] [Reference Citation Analysis]
11 Nishiga M, Horie T, Kuwabara Y, Nagao K, Baba O, Nakao T, Nishino T, Hakuno D, Nakashima Y, Nishi H, Nakazeki F, Ide Y, Koyama S, Kimura M, Hanada R, Nakamura T, Inada T, Hasegawa K, Conway SJ, Kita T, Kimura T, Ono K. MicroRNA-33 Controls Adaptive Fibrotic Response in the Remodeling Heart by Preserving Lipid Raft Cholesterol. Circ Res 2017;120:835-47. [PMID: 27920122 DOI: 10.1161/CIRCRESAHA.116.309528] [Cited by in Crossref: 42] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
12 Henderson J, Pryzborski S, Stratton R, O'Reilly S. Wnt antagonist DKK-1 levels in systemic sclerosis are lower in skin but not in blood and are regulated by microRNA33a-3p. Exp Dermatol 2021;30:162-8. [PMID: 32592422 DOI: 10.1111/exd.14136] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Sundrani DP, Karkhanis AR, Joshi SR. Peroxisome Proliferator-Activated Receptors (PPAR), fatty acids and microRNAs: Implications in women delivering low birth weight babies. Syst Biol Reprod Med 2021;67:24-41. [PMID: 33719831 DOI: 10.1080/19396368.2020.1858994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Formichi C, Nigi L, Grieco GE, Maccora C, Fignani D, Brusco N, Licata G, Sebastiani G, Dotta F. Non-Coding RNAs: Novel Players in Insulin Resistance and Related Diseases. Int J Mol Sci 2021;22:7716. [PMID: 34299336 DOI: 10.3390/ijms22147716] [Reference Citation Analysis]
15 Zeng XY, Wang J, Zhang YQ, Wu JF. Relationship between microRNAs and signaling pathways associated with hepatic stellate cells. Shijie Huaren Xiaohua Zazhi 2015; 23(1): 1-7 [DOI: 10.11569/wcjd.v23.i1.1] [Reference Citation Analysis]
16 Botello-Manilla AE, Chávez-Tapia NC, Uribe M, Nuño-Lámbarri N. Genetics and epigenetics purpose in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2020;14:733-48. [PMID: 32552211 DOI: 10.1080/17474124.2020.1780915] [Reference Citation Analysis]
17 Dewidar B, Soukupova J, Fabregat I, Dooley S. TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis: Updated. Curr Pathobiol Rep 2015;3:291-305. [DOI: 10.1007/s40139-015-0089-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
18 Wang J, Guo L, Shen D, Xu X, Wang J, Han S, He W. The Role of c-SKI in Regulation of TGFβ-Induced Human Cardiac Fibroblast Proliferation and ECM Protein Expression. J Cell Biochem 2017;118:1911-20. [PMID: 28214335 DOI: 10.1002/jcb.25935] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
19 Zou XZ, Liu T, Gong ZC, Hu CP, Zhang Z. MicroRNAs-mediated epithelial-mesenchymal transition in fibrotic diseases. Eur J Pharmacol 2017;796:190-206. [PMID: 27916556 DOI: 10.1016/j.ejphar.2016.12.003] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 6.7] [Reference Citation Analysis]
20 Ran LJ, Liang J, Deng X. MicroRNAs regulate hepatic fibrosis via TGF-β/Smad pathway. Shijie Huaren Xiaohua Zazhi 2017; 25(2): 166-171 [DOI: 10.11569/wcjd.v25.i2.166] [Cited by in CrossRef: 1] [Article Influence: 0.2] [Reference Citation Analysis]
21 Chen Y, Yuan B, Wu Z, Dong Y, Zhang L, Zeng Z. Microarray profiling of circular RNAs and the potential regulatory role of hsa_circ_0071410 in the activated human hepatic stellate cell induced by irradiation. Gene 2017;629:35-42. [PMID: 28774651 DOI: 10.1016/j.gene.2017.07.078] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 9.0] [Reference Citation Analysis]
22 Wang X, Wu X, Zhang A, Wang S, Hu C, Chen W, Shen Y, Tan R, Sun Y, Xu Q. Targeting the PDGF-B/PDGFR-β Interface with Destruxin A5 to Selectively Block PDGF-BB/PDGFR-ββ Signaling and Attenuate Liver Fibrosis. EBioMedicine 2016;7:146-56. [PMID: 27322468 DOI: 10.1016/j.ebiom.2016.03.042] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
23 Lee SY, Lee J, Lee H, Kim B, Lew J, Baek N, Kim SH. MicroRNA134 Mediated Upregulation of JNK and Downregulation of NFkB Signalings Are Critically Involved in Dieckol Induced Antihepatic Fibrosis. J Agric Food Chem. 2016;64:5508-5514. [PMID: 27321552 DOI: 10.1021/acs.jafc.6b01945] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
24 Liu H, Wang X, Liu S, Li H, Yuan X, Feng B, Bai H, Zhao B, Chu Y, Li H. Effects and mechanism of miR-23b on glucose-mediated epithelial-to-mesenchymal transition in diabetic nephropathy. Int J Biochem Cell Biol 2016;70:149-60. [PMID: 26646104 DOI: 10.1016/j.biocel.2015.11.016] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
25 Musso G, Cassader M, Gambino R. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nat Rev Drug Discov. 2016;15:249-274. [PMID: 26794269 DOI: 10.1038/nrd.2015.3] [Cited by in Crossref: 229] [Cited by in F6Publishing: 222] [Article Influence: 38.2] [Reference Citation Analysis]
26 Liang C, Yu XJ, Guo XZ, Sun MH, Wang Z, Song Y, Ni QX, Li HY, Mukaida N, Li YY. MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine. Oncotarget 2015;6:14440-55. [PMID: 25971209 DOI: 10.18632/oncotarget.3885] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 7.3] [Reference Citation Analysis]
27 Zhang C, Zhang Y, Ding W, Lin Y, Huang Z, Luo Q. MiR-33a suppresses breast cancer cell proliferation and metastasis by targeting ADAM9 and ROS1. Protein Cell. 2015;6:881-889. [PMID: 26507842 DOI: 10.1007/s13238-015-0223-8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 5.7] [Reference Citation Analysis]
28 Kostopoulou F, Malizos KN, Papathanasiou I, Tsezou A. MicroRNA-33a regulates cholesterol synthesis and cholesterol efflux-related genes in osteoarthritic chondrocytes. Arthritis Res Ther 2015;17:42. [PMID: 25880168 DOI: 10.1186/s13075-015-0556-y] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
29 Tan Y, Ge G, Pan T, Wen D, Gan J. Serum MiRNA panel as potential biomarkers for chronic hepatitis B with persistently normal alanine aminotransferase. Clin Chim Acta 2015;451:232-9. [PMID: 26483130 DOI: 10.1016/j.cca.2015.10.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
30 Xu X, Hong P, Wang Z, Tang Z, Li K. MicroRNAs in Transforming Growth Factor-Beta Signaling Pathway Associated With Fibrosis Involving Different Systems of the Human Body. Front Mol Biosci 2021;8:707461. [PMID: 34381815 DOI: 10.3389/fmolb.2021.707461] [Reference Citation Analysis]
31 Zhang AH, Jiang N, Wang XQ, Tan RX. Galewone, an Anti-Fibrotic Polyketide from Daldinia eschscholzii with an Undescribed Carbon Skeleton. Sci Rep 2019;9:14316. [PMID: 31586120 DOI: 10.1038/s41598-019-50868-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Page A, Mann DA, Mann J. The mechanisms of HSC activation and epigenetic regulation of HSCs phenotypes. Curr Pathobiol Rep 2014;2:163-70. [PMID: 27413631 DOI: 10.1007/s40139-014-0052-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
33 Tan S, Liu H, Ke B, Jiang J, Wu B. The peripheral CB1 receptor antagonist JD5037 attenuates liver fibrosis via a CB1 receptor/β-arrestin1/Akt pathway. Br J Pharmacol 2020;177:2830-47. [PMID: 32017042 DOI: 10.1111/bph.15010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
34 Kitano M, Bloomston PM. Hepatic Stellate Cells and microRNAs in Pathogenesis of Liver Fibrosis. J Clin Med. 2016;5. [PMID: 26999230 DOI: 10.3390/jcm5030038] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 10.3] [Reference Citation Analysis]
35 Dongiovanni P, Meroni M, Longo M, Fargion S, Fracanzani AL. miRNA Signature in NAFLD: A Turning Point for a Non-Invasive Diagnosis. Int J Mol Sci 2018;19:E3966. [PMID: 30544653 DOI: 10.3390/ijms19123966] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 11.5] [Reference Citation Analysis]
36 Kumar P, Raeman R, Chopyk DM, Smith T, Verma K, Liu Y, Anania FA. Adiponectin inhibits hepatic stellate cell activation by targeting the PTEN/AKT pathway. Biochim Biophys Acta Mol Basis Dis. 2018;1864:3537-3545. [PMID: 30293572 DOI: 10.1016/j.bbadis.2018.08.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
37 Huang CF, Sun CC, Zhao F, Zhang YD, Li DJ. miR-33a levels in hepatic and serum after chronic HBV-induced fibrosis. J Gastroenterol. 2015;50:480-490. [PMID: 25155445 DOI: 10.1007/s00535-014-0986-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
38 Wang Y, Tian Y. miRNA for diagnosis and clinical implications of human hepatocellular carcinoma. Hepatol Res 2016;46:89-99. [PMID: 26284466 DOI: 10.1111/hepr.12571] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
39 Duong TE, Hagood JS. Epigenetic Regulation of Myofibroblast Phenotypes in Fibrosis. Curr Pathobiol Rep 2018;6:79-96. [PMID: 30271681 DOI: 10.1007/s40139-018-0155-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
40 Li X, Qiu J, Liu H, Deng Y, Hu S, Hu J, Wang Y, Wang J. MicroRNA-33a negatively regulates myoblast proliferation by targeting IGF1, follistatin and cyclin D1. Biosci Rep 2020;40:BSR20191327. [PMID: 32436962 DOI: 10.1042/BSR20191327] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
41 Afonso MB, Rodrigues PM, Simão AL, Castro RE. Circulating microRNAs as Potential Biomarkers in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma. J Clin Med 2016;5:E30. [PMID: 26950158 DOI: 10.3390/jcm5030030] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 8.5] [Reference Citation Analysis]